How India Exports Digoxin to the World

Digoxin, a critical cardiac glycoside, has a well-established presence in the U.S. pharmaceutical market. According to the FDA's Orange Book, numerous Abbreviated New Drug Applications (ANDAs) have been approved for digoxin, indicating a robust generic market. The most recent approval was granted in March 2025, reflecting ongoing interest and investment in this medication. Notably, there are no current import alerts or significant regulatory actions against digoxin, suggesting compliance with FDA standards.

The U.S. remains the primary destination for Indian digoxin exports, accounting for 51.4% of the total export value. This substantial market share underscores the importance of maintaining stringent quality standards and regulatory compliance to sustain and expand market presence.

In the European Union and the United Kingdom, digoxin is subject to rigorous regulatory oversight. Marketing authorizations are granted by the European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA), respectively. Manufacturers must adhere to the EU's Good Manufacturing Practice (GMP) guidelines, ensuring consistent product quality and safety. As of March 2026, there have been no recent regulatory actions or changes affecting digoxin's status in these regions.

Digoxin is included in the World Health Organization's (WHO) 24th Model List of Essential Medicines, published in September 2025. This inclusion highlights its critical role in treating cardiovascular conditions globally. The medication is recognized across major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality and efficacy benchmarks worldwide.

In India, digoxin is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not imposed a ceiling price on digoxin, allowing market-driven pricing. For export purposes, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations.

Digoxin's primary patents have long expired, leading to a competitive generic market. This environment fosters affordability and accessibility, benefiting both healthcare providers and patients.

In June 2025, the Indian government implemented stricter quality control measures for pharmaceutical exports, including digoxin, to enhance global competitiveness and compliance. In August 2025, the FDA approved a new generic formulation of digoxin, further intensifying market competition. In October 2025, the WHO updated its Essential Medicines List, reaffirming digoxin's inclusion and emphasizing its importance in global health. In December 2025, the EMA introduced revised GMP guidelines, affecting digoxin manufacturers exporting to the EU. In February 2026, the NPPA conducted a review of cardiovascular drug pricing, including digoxin, to ensure affordability and accessibility.

These developments underscore the dynamic regulatory landscape surrounding digoxin, necessitating continuous monitoring and adaptation by stakeholders to maintain compliance and market viability.

India's pharmaceutical industry, renowned for its generic drug production, heavily relies on China for Key Starting Materials (KSMs) essential in Active Pharmaceutical Ingredient (API) synthesis. Approximately 60–70% of KSMs are imported from China, making India vulnerable to supply chain disruptions. This dependency is particularly concerning for drugs like Digoxin, where any interruption in KSM supply can halt API production, leading to potential shortages.

Recent geopolitical tensions have exacerbated these risks. In June 2025, Iran's parliament voted to close the Strait of Hormuz, a critical chokepoint through which 20% of global oil transits. This action threatened to disrupt global supply chains, including the pharmaceutical sector, by increasing transportation costs and causing delays. (pharmasource.global) Such events highlight the fragility of India's API supply chain due to its reliance on Chinese KSMs and the potential for geopolitical events to disrupt essential material flows.

Our proprietary trade data from 2022 to 2026 indicates that the top five Indian exporters of Digoxin account for 60.3% of total exports, with SUN PHARMACEUTICAL INDUSTRIES LIMITED alone contributing 45.6%. This high supplier concentration poses a significant risk; any operational or regulatory issues affecting these key players could severely impact global Digoxin availability.

To mitigate such risks, the Indian government introduced the Production Linked Incentive (PLI) scheme in October 2024, aiming to boost domestic API and KSM production. Two greenfield plants were inaugurated under this scheme to manufacture critical molecules, reducing import dependence. While this initiative is a positive step, its effectiveness in diversifying the supplier base for Digoxin remains to be seen.

Geopolitical tensions have significantly impacted global shipping routes critical to pharmaceutical supply chains. The closure of the Strait of Hormuz in June 2025 led to increased transportation costs and delays, affecting the timely delivery of APIs and finished pharmaceutical products. (pharmasource.global) Similarly, conflicts in the Red Sea region have disrupted shipping lanes, causing price fluctuations and supply chain uncertainties. (pharmasource.global)

These disruptions have prompted regulatory bodies like the FDA to monitor and address potential drug shortages. The FDA actively works with industry partners to identify and mitigate supply chain vulnerabilities, ensuring the continued availability of essential medications. However, the effectiveness of these measures in preventing Digoxin shortages amid ongoing geopolitical tensions remains a concern.

• Diversify KSM Sources: Encourage Indian manufacturers to source KSMs from multiple countries to reduce dependency on China and enhance supply chain resilience.

• Strengthen Domestic Production: Accelerate the implementation of the PLI scheme to boost domestic production of KSMs and APIs, reducing reliance on imports.

• Enhance Supplier Base: Promote the growth of small and medium-sized enterprises (SMEs) in the pharmaceutical sector to diversify the supplier base and reduce concentration risks.

• Develop Contingency Plans: Establish robust contingency plans to address potential disruptions in shipping routes, including alternative transportation methods and strategic stockpiling of critical materials.

• Monitor Regulatory Compliance: Ensure continuous compliance with international quality standards to prevent regulatory actions that could disrupt exports.

RISK_LEVEL: HIGH